Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295633 · ClinicalTrials.gov registry record · Phase 3
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 565
- Enrollment target
NCT00295633: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00295633 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 565 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00295633, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 565 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
Primary Outcome
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
Interventions
- DRUG Placebo
- DRUG Saxagliptin
- DRUG pioglitazone
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00295633 record still lists
NCT00295633 is an interventional study that assigns participants to a tested intervention. The registered 565 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00295633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00295633 about?
NCT00295633 is a clinical study titled "A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone". The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
What is the current status of trial NCT00295633?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 565 participants. The study started on 2006-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00295633?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG), pioglitazone (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00295633?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00295633's enrollment target sits among peer trials
565 667th of 2000 higher than 1,333 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia